1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 45, 07/Nov/2024
  4. Article
Perspective Open Access
Like 0
Download

Abstract

The COVID-19 pandemic and related preventive measures reduced influenza virus circulation, notably causing the disappearance of the B/Yamagata lineage of influenza viruses. In this Perspective, we discuss the implications that this development may have for global influenza epidemiology, and the adjustments that may need to be implemented concerning surveillance strategies and practices, laboratory safety protocols, and influenza vaccine formulations. The disappearance of the B/Yamagata lineage might indeed alter the dynamics of the influenza disease burden (although in a way that is difficult to predict at the moment), and associated diagnostic practices, and may also necessitate updated biosafety levels and revised influenza surveillance strategies. Furthermore, the World Health Organization (WHO) recommended in September 2023 the exclusion of B/Yamagata antigens from future vaccines, with a shift towards trivalent vaccines or modified quadrivalent vaccines; this new scenario underscores the importance of robust global respiratory virus surveillance, effective communication with healthcare professionals and the population to maintain trust in vaccines, and a collaborative approach among health policymakers and vaccine manufacturers to navigate this epidemiological change.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.45.2400196
2024-11-07
2024-12-26
/content/10.2807/1560-7917.ES.2024.29.45.2400196
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/45/eurosurv-29-45-8.html?itemId=/content/10.2807/1560-7917.ES.2024.29.45.2400196&mimeType=html&fmt=ahah

References

  1. Dhanasekaran V, Sullivan S, Edwards KM, Xie R, Khvorov A, Valkenburg SA, et al. Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination. Nat Commun. 2022;13(1):1721.  https://doi.org/10.1038/s41467-022-29402-5 
  2. Paget J, Caini S, Del Riccio M, van Waarden W, Meijer A. Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines? Euro Surveill. 2022;27(39):2200753.  https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200753 
  3. Vijaykrishna D, Holmes EC, Joseph U, Fourment M, Su YC, Halpin R, et al. The contrasting phylodynamics of human influenza B viruses. eLife. 2015;4:e05055.  https://doi.org/10.7554/eLife.05055 
  4. Virk RK, Jayakumar J, Mendenhall IH, Moorthy M, Lam P, Linster M, et al. Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity. Proc Natl Acad Sci USA. 2020;117(1):619-28.  https://doi.org/10.1073/pnas.1916585116 
  5. Tan Y, Guan W, Lam TT, Pan S, Wu S, Zhan Y, et al. Differing epidemiological dynamics of influenza B virus lineages in Guangzhou, southern China, 2009-2010. J Virol. 2013;87(22):12447-56.  https://doi.org/10.1128/JVI.01039-13 
  6. Caini S, Kusznierz G, Garate VV, Wangchuk S, Thapa B, de Paula Júnior FJ, et al. Global Influenza B Study team. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. PLoS One. 2019;14(9):e0222381.  https://doi.org/10.1371/journal.pone.0222381 
  7. Sočan M, Prosenc K, Učakar V, Berginc N. A comparison of the demographic and clinical characteristics of laboratory-confirmed influenza B Yamagata and Victoria lineage infection. J Clin Virol. 2014;61(1):156-60.  https://doi.org/10.1016/j.jcv.2014.06.018 
  8. Marchi S, Bruttini M, Milano G, Manini I, Chironna M, Pariani E, et al. Prevalence of influenza B/Yamagata viruses from season 2012/2013 to 2021/2022 in Italy as an indication of a potential lineage extinction. Influenza Other Respir Viruses. 2024;18(9):e13359.  https://doi.org/10.1111/irv.13359 
  9. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009;459(7249):931-9.  https://doi.org/10.1038/nature08157 
  10. Arduino MJ, Arndt WD, Bailin H, Baumann RG, Bradbury RS, Brandt ME, et al. Biosafety in microbiological and biomedical laboratories (BMBL). 6th Edition. Atlanta: Centers for Disease Control and Prevention; 2020. Available from: https://www.cdc.gov/labs/bmbl/?CDC_AAref_Val=https://www.cdc.gov/labs/BMBL.html
  11. Eurosurveillance Editorial team. Meijer A, Brown CS, Paget WJ. E-alert 13 April: Worldwide laboratory distribution of influenza A/H2N2 virus similar to 1957-58 pandemic strain, labs asked to destroy all samples immediately. Euro Surveill. 2005;10(15):2681.
  12. Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ. 1998;76(Suppl 2) Suppl 2;22-5. PMID:10063669
  13. Institute of Medicine (US) Forum on Emerging Infections. Considerations for viral disease eradication: lessons learned and future strategies. Knobler S, Lederberg J, Pray LA, editors. Washington (DC): National Academies Press (US); 2002. Available from: https://nap.nationalacademies.org/catalog/10424/considerations-for-viral-disease-eradication-lessons-learned-and-future-strategies
  14. Koutsakos M, Rockman S, Krammer F. Is eradication of influenza B viruses possible? Lancet Infect Dis. 2024;24(5):451-3.  https://doi.org/10.1016/S1473-3099(24)00132-4 
  15. Zanobini P, Bonaccorsi G, Lorini C, Haag M, McGovern I, Paget J, et al. Global patterns of seasonal influenza activity, duration of activity and virus (sub)type circulation from 2010 to 2020. Influenza Other Respir Viruses. 2022;16(4):696-706.  https://doi.org/10.1111/irv.12969 
  16. Nakajima K, Desselberger U, Palese P. Recent human influenza A (H1N1) viruses are closely related genetically to strains isolated in 1950. Nature. 1978;274(5669):334-9.  https://doi.org/10.1038/274334a0 
  17. Rozo M, Gronvall GK. The reemergent 1977 H1N1 strain and the gain-of-function debate. MBio. 2015;6(4):e01013-5.  https://doi.org/10.1128/mBio.01013-15 
  18. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season. Geneva: WHO; 2023. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-southern-hemisphere-influenza-season
  19. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season. Geneva: WHO; 2024. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season
  20. Sánchez-de Prada L, Rojo-Rello S, Domínguez-Gil M, Tamayo-Gómez E, Ortiz de Lejarazu-Leonardo R, Eiros JM, et al. Influenza B lineages have more in common than meets the eye. trivalent influenza vaccines trigger heterotypic antibodies against both influenza B viruses. Front Microbiol. 2021;12:737216.  https://doi.org/10.3389/fmicb.2021.737216 
  21. Caini S, Meijer A, Nunes MC, Henaff L, Zounon M, Boudewijns B, et al. Probable extinction of influenza B/Yamagata and its public health implications: a systematic literature review and assessment of global surveillance databases. Lancet Microbe. 2024;5(8):100851.  https://doi.org/10.1016/S2666-5247(24)00066-1 
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error